Has Bipolar Disorder become a predominantly female gender related condition? Analysis of recently published large sample studies

Bernardo Dell'Osso (bernardo.dellosso@unimi.it)  
UNIMI  https://orcid.org/0000-0001-9370-5365

Rita Cafaro  
Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.

Terence A. Ketter  
Department of Psychiatry and Behavioural Sciences, Stanford University, CA, USA.

Short communication

Keywords: Bipolar Disorder, gender distribution, psychiatric disorder

DOI: https://doi.org/10.21203/rs.3.rs-53476/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Bipolar Disorders are disabling and severe psychiatric disorders, commonly perceived as equally affecting both men and women. The prevalence of BD in the general population has been growing over the last decade, however, few epidemiological studies are available regarding BD gender distribution, leaving unanswered the question whether the often reported increment of BD diagnosis could be gender specific. In fact, BD in female patients can often be misdiagnosed as MDD, leaving such women non correctly treated for longer times than their male counterparts.

From this perspective, we searched literature for large sample (>1000 subjects) studies published in the last decade (2010 onward) on BD patients. We included ten large sample studies that reported the gender distribution of their samples, and we therefore analysed them. Our results show a higher preponderance of female patients in every sample and sub-sample of BDI and BDII, supporting our hypothesis of an increase in BD diagnosis in females. BD in women presents with higher rates of rapid cycling, depressive polarity and suicide attempts, characteristics of non inferior severity compared to males; prompt recognition and adequate treatment of BD is therefore crucial to reduce risks and improve quality of life of affected women. In this regard, our results could lead the way for national or international epidemiological studies with the aim of more accurately assessing gender-specific prevalence of BD.

Introduction

Bipolar Disorder (BD) has been traditionally included among psychiatric conditions with no gender difference in terms of lifetime prevalence in the general population,\textsuperscript{1-4} in contrast to unipolar Major Depressive Disorder (MDD), which has consistently shown a higher prevalence in the female gender.\textsuperscript{5-7} However, some studies showed specific differences in the clinical course as well as across various behavioural and social outcomes of BD in individuals with male versus female gender. For instance, early (pre-teen) age of onset of first mania,\textsuperscript{3,8} substance use disorders,\textsuperscript{9,10} and legal problems,\textsuperscript{11} were reported to be more common in men, while rapid cycling,\textsuperscript{12,13} depressive episodes,\textsuperscript{14} mixed mania,\textsuperscript{14,15} and attempted or completed suicides,\textsuperscript{10,16} have been reported to be more frequent in women. Indeed, hypomania, and consequently BD type II (BDII), has commonly been more frequently associated with female gender,\textsuperscript{17-19} while no significant gender difference has been reported in lifetime prevalence of BD type I (BDI).\textsuperscript{14}

The overall limited epidemiological studies about BD conducted in the last decade showed increasing lifetime prevalence of BD in the general population\textsuperscript{20} possibly due to better diagnostic instruments, especially with the implementation of DSM-IV diagnostic criteria.\textsuperscript{21}

On the other hand, these studies did not evaluate the gender composition of recruited samples, leaving unanswered the question whether the better understanding of the disease lead to an improvement in its recognition in the female gender, in which misdiagnosis with unipolar MDD occurs frequently.\textsuperscript{22-24} In this regard, the recognition of an epidemiological trend of gender specificity in BD could help physicians to
pursue prompter diagnosis and implement more effective treatments, which are extremely important considering that use of antidepressants (i.e., misdiagnosis unipolar MDD) might lead to inefficacy for misdiagnosed (actually bipolar) depression, treatment-emergent (hypo)manic switching, onset of rapid cycling and, thus, negatively influence the course of the disease.\textsuperscript{25}

In light of these considerations, we aimed to analyse the gender composition of large samples studies on BD patients published in the last decade (from 2010 onward), to evaluate a possible modification in the trend of representation of the disease in the two genders.

**Methods**

An electronic systematic review within the online databases PubMed, Medline, PsychINFO, and Cochrane Library was conducted up to May 2020. Keywords used were: “bipolar disorder” OR “mania” AND “gender” OR “gender difference(s)” AND “national cohort” OR “multicentric studies”. The results were filtered by year of publication (2011-2020) and number of patients included in the study (> 1,000). We then proceeded to exclude studies not adherent to criteria and incomplete studies not providing information on sample composition in terms of (sub)diagnosis and gender distribution.

**Results**

Ten clinical studies published in the last ten years, analysing data from more than 1000 bipolar patients per sample, met our inclusion criteria and are therefore presented and discussed here (Table 1). In aggregate, 47,878 patients with BD were included in these studies.

Two of these studies were conducted in Sweden, one including bipolar patients enrolled in the national registry of the years 2001-2002 (n = 6,618),\textsuperscript{26} while the other included bipolar patients from the Swedish National Quality Assurance Register for Bipolar Disorder (BipoläR), recruiting patients from 2004 to 2011 (n = 7,136).\textsuperscript{27} Another study was conducted in the United Kingdom (U.K.), analysing data from patients included in “The Health Improvement Network” (THIN), from 2000 to 2014 (n = 17,341);\textsuperscript{28} THIN is a database of primary care electronics health records representative of the general U.K. population in terms of age, gender, medical conditions, and death rates, and has been validated for research purposes against experimental and observational evidences. Similarly, one study was conducted in Korea and was based on the Health Insurance Review and Assessment Service – National Patient Sample (HIRA-NPS) records of 2010, 2011 and 2013; importantly, validity and representativeness of HIRA-NPS data have been extensively demonstrated.\textsuperscript{29} However, as there is no continuity between data for different years, in order to avoid duplicates, we included in our review only data from 2013 (n = 2,626).\textsuperscript{30} Two studies were based in the United States of America (U.S.A.); one of them analysed data from the “Systematic Treatment Enhancement Program for Bipolar Disorder” (STEP-BD), a nationwide database collected from 1999 to 2005 (n = 3,563).\textsuperscript{31} The other was based on the Mayo Clinic Biobank, started in 2009 and including patients recruited until 2018 (n = 1,465).\textsuperscript{32} Yet another study was an Italian study collecting data in the
context of the National Epidemiological Research on Bipolar Disorder (RENDiBi) project, in which patients were recruited from April 2014 to March 2015 \( (n = 1,675) \). Finally, three studies were based on multinational multicentric databases; one was the Wide AmbispectiVE study of the clinical management and burden of BD (WAVE-BD), recruiting patients from April 2010 to June 2011 \( (n = 2,896) \). Another study collected data from the ConLiGen database \( (n = 2,563) \), while the last one included data collected from ConLiGen, Bonn-Mannheim and PsyCourse databases \( (n = 1,995, \) BDI patients only).\(^{36}\) Nine out of ten studies analysed samples of both BDI and BDII patients, while one study only analysed a sample of BDI patients. All the evaluated studies described the general distribution of their samples in terms of gender, reporting a higher prevalence of female patients, with female patient proportions ranging from \( 57.4\% \) (RENDiBi Study) to \( 65.0\% \) (WAVE-BD) (Figure 1a). Of these, three studies (Mayo Clinic Biobank, RENDiBi Study, WAVE-BD) described the distribution of their samples in terms of BDI and BDII (Mayo Clinic Biobank: 69.4\% of BDI, RENDiBi Study: 62.2\% of BDI, WAVE-BD: 68.7\% of BDI), while one of them (BipoläR) further categorised patients in BDI (47.1\%), BDII (38.1\%), and Bipolar Disorder – Not Otherwise Specified (BD NOS) (14.8\%). In these four studies, a higher prevalence of BDI diagnosis among women can be found (Figure 1c). Moreover, the Mayo Clinic Biobank study reported the gender distribution of the sub-samples BD-I (F = 58.6\%) and BD-II (F = 66.1\%), while the BipoläR study reported the gender distribution in the three sub-samples BDI (F = 57.3\%), BDII (F = 64.9\%), and BD NOS (F = 64.4\%). As shown, both these studies reported a higher prevalence of female versus male patients in every sub-sample (Figure 1b).

Finally, one study evaluated a sample of BDI patients only, reporting a higher prevalence of female versus male patients (55.1\%).

**Discussion**

As shown in the results, 100\% (ten out of ten) of our selected large samples studies \( (n > 1,000) \) published in the last ten years \( (2011-2020) \), showed a predominance of female gender in their samples of bipolar patients. These results could support our hypothesis of a relatively recent increase in BD prevalence among individuals with female gender. Even though data published in the Global Burden of Disease Study of 2013 seem to support the findings of a higher prevalence of BD in the female gender\(^{37}\), our results seem to be in contradiction with previously published literature about BD prevalence in the two genders.\(^{1-4,14}\) Causes for this difference could lay in the size of the samples analysed, being that the majority of the studies presented in literature analyse much smaller samples. Moreover, one could argue that the higher percentage of females diagnosed with BD-II could interfere with the gender distribution of the samples analysed, and therefore be the cause of our findings. However, of note, Bobo et al.,\(^{32}\) Buoli et al.,\(^{33}\) Karanti et al.,\(^{27}\) and Vieta et al.,\(^{34}\) had a higher proportion of BDI patients in their samples, and Kalman et al.\(^{36}\) only had BDI patients in their sample. Findings of a higher prevalence of female patients in these four studies could further support our hypothesis, being BDI the type of BD traditionally more commonly associated with equal prevalence in the two genders.\(^{2,3} \)
Even though not all of the studies discussed here are epidemiological, all of them represent the gender distribution of wide national or international coverage studies, with high numbers of patients, and therefore report a fairly realistic picture of the distribution of the disease in the population to which they refer. Buoli et al. \(^{33}\) analysed the sample of a nationwide epidemiological study, Hayes et al. \(^{28}\) and Yoon et al. \(^{30}\) recruited patients from samples representative of the national population, while Crump et al. \(^{26}\) recruited patients from the Swedish National Registry, which included every person at least 20 years of age that lived in Sweden for at least two years as of January 1, 2003.

Overall, the gender distribution of BD reported in these studies, along with the increase of BD diagnosis in the last decade, \(^{20}\) could be signals of more efficient BD diagnosis, especially in the female gender. Since female gender in BD has already been associated with higher rates of rapid cycling, \(^{38}\) dysphoria, and lifetime prevalence of depressive episodes, \(^{39}\) and suicide attempts, \(^{10}\) indicating that BD in women can exhibit characteristics of non-inferior severity of illness and reduced quality of life, compared to their male counterparts, prompt recognition of BD in female patients is crucial in order to provide more adequate treatment. In particular, the frequent observation of a prevalent depressive polarity in female patients, \(^{10}\) with more frequent first manifestation of BD through a major depressive episode (MDE) and the higher lifetime number of MDEs, represent significant challenges for clinicians who may misdiagnose them as affected by unipolar MDD and consequently treat them with antidepressants rather than with mood stabilizers and atypical antipsychotics, a treatment that, particularly if administered in monotherapy, could concur in the onset of rapid cycling. \(^{40}\) In this regard, although some studies in literature support the use of antidepressants as adjunctive short-term treatment in bipolar depression \(^{41}\), data on the topic are inconsistent, \(^{42}\) and antidepressants alone yield a high risk for manic switch and therefore mood stabilizers are still the cornerstone of bipolar disorders treatment. \(^{43}\)

Moreover, BD in women poses a significant burden on pregnancy, with a higher risk of adverse pregnancy outcomes and a higher frequency of relapses during the postpartum period, \(^{44-46}\) making prophylactic medication during pregnancy fundamental in order to maintain mood stability postpartum. \(^{45}\) Of note, the correlation between the physiology of pregnancy and BD relapses could underlay hormonal and endocrinological influence on BD symptoms and presentation, as it has already been demonstrated for unipolar MDD. \(^{47-49}\) The extensively reported correlations between sex hormones and mood dysregulation in women, could be significant also for BD, not only in terms of prevalence, but also for providing better care for female BD patients, which could benefit from personalized and hormonal treatments, as it already happens for unipolar MDD. \(^{49}\) It has already been suggested, in this regard, that women treated for BD show greater degrees of menstrual-entrained mood fluctuations, which could be mitigated by mood stabilizing treatments (i.e. Lamotrigine). \(^{50}\)

In conclusion, as BDs represent highly comorbid, disabling, difficult-to-treat and life-threatening conditions, clinicians should be aware of the recently reported increase in the prevalence of such conditions in the female gender and pay additional attention in the differential diagnosis with unipolar MDD, particularly when the first manifestation of BD is represented by a MDE. Prompter diagnosis and
appropriate treatment for females with BD, in fact, could reduce acute inefficacy, longer-term relapses, suicide attempts, treatment-emergent affective switching, and onset of rapid-cycling.

Although in the ten large samples studies analysed here it is possible to identify a higher prevalence of female BD patients, the majority of these studies are not epidemiological, and their samples are collected over many years, many in BD Specialty Clinics, which commonly report having more female than male patients. In this regard, female patients, especially in younger generations, are more often willing to seek help for their symptoms, leading to a possible sampling bias. On the other hand, the often reported comorbid substance use disorders in male patients might concur in the fewer men seeking treatment in Bipolar Disorder Specialty Clinics, enhancing this possible sampling bias. Adding to this, female patients often seek help for ruminative thinking associated to life events stressors, and ruminative thinking is often interpreted as a sign of depression. To avoid these confounding factors, nationwide or international epidemiological studies are needed in order to confirm our preliminary observation.

Being the samples analysed here only based on longitudinal diagnosis of BD, another limitation of our study is the lack of data on mood presentation at the time of the studies, therefore not addressing one of the greatest differences in BDs presentation between genders.

Moreover, the studies analysed here recruited samples from specific areas or nations. It could be, from this point of view, that our conclusions cannot be extended to the international population but are only true for the specific regions of interest. It is well known, in fact, that the gender distribution of the general population varies across the world, with some countries (especially eastern countries) with a predominant male population. It is therefore possible that, for these countries, further and more specific studies on the subject should be carried out.

Lastly, even though the higher number of reported BD diagnosis in the last years could be connected to better diagnostic criteria implemented in the most recent editions of the DSM, on the other hand, more comprising diagnostic criteria could misleadingly help diagnose BD when it is not present, and therefore lead to a selection bias. In this regard, a right diagnose and a thorough follow-up are extremely important in order to provide the right treatment to patients presenting with depressive symptoms.

**Declarations**

*Ethics approval and consent to participate*

Not applicable

*Consent for publication*

Not applicable

*Availability of data and material*
All data generated or analysed during this study are included in this published article.

**Competing interests**

In the last three years, Dr Dell’Osso has received lecture honoraria from Angelini, Lundbeck, Janssen, Pfizer, Neuraxpharm, Arcapharma and Livanova; Dr. Ketter has received grants from Agency for Healthcare Research and Quality, personal fees from Acadia Pharmaceuticals, personal fees from Allergan Pharmaceuticals, personal fees and other from Janssen Pharmaceuticals, personal fees from Myriad Genetic Laboratories, Inc., personal fees from Navigen, personal fees from Otsuka Pharmaceuticals, grants and personal fees from Sunovion Pharmaceuticals, personal fees from Supernus Pharmaceuticals, personal fees from Teva Pharmaceuticals, personal fees from GlaxoSmithKline, grants from Merck & Co., Inc., personal fees from American Psychiatric Publishing, Inc., outside the submitted work. Dr. Cafaro reports no financial relationships with commercial interests.

**Funding**

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

**Authors’ contributions**

All authors contributed equally to this manuscript.

**Acknowledgements**

Not applicable

**References**

1. Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. *Psychol Med.* 1988; 18(1):141-153. doi:10.1017/S0033291700001975.

2. Mitchell PB, Slade T, Andrews G. Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey. *Psychol Med.* 2004; 34(5):777-785. doi:10.1017/S0033291703001636.

3. Grant BF, Stinson FS, Hasin DS, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry.* 2005; 66(10):1205-1215. doi:10.4088/JCP.v66n1001.

4. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. *Arch Gen Psychiatry.* 2007; 64(5):543-552. doi:10.1001/archpsyc.64.5.543.
5 Bijl R V., de Graaf R, Ravelli A, Smit F, Vollebergh WAM. Gender and age-specific first incidence of DSM-III-R psychiatric disorders in the general population. Results from the Netherlands mental health survey and incidence study (NEMESIS). *Soc Psychiatry Psychiatr Epidemiol*. 2002; 37(8):372-379. doi:10.1007/s00127-002-0566-3.

6 Kessler RC. Epidemiology of women and depression. In: *Journal of Affective Disorders*. Vol 74. Elsevier; 2003:5-13. doi:10.1016/S0165-0327(02)00426-3.

7 Leach LS, Christensen H, Mackinnon AJ, Windsor TD, Butterworth P. Gender differences in depression and anxiety across the adult lifespan: The role of psychosocial mediators. *Soc Psychiatry Psychiatr Epidemiol*. 2008; 43(12):983-998. doi:10.1007/s00127-008-0388-z.

8 Kennedy N, Boydell J, Kalidindi S, et al. Gender differences in incidence and age at onset of mania and bipolar disorder over a 35-year period in Camberwell, England. *Am J Psychiatry*. 2005; 162(2):257-262. doi:10.1176/appi.ajp.162.2.257.

9 Kessing LV. Gender differences in the phenomenology of bipolar disorder. *Bipolar Disord*. 2004; 6(5):421-425. doi:10.1111/j.1399-5618.2004.00135.x.

10 Nivoli AMA, Pacchiarotti I, Rosa AR, et al. Gender differences in a cohort study of 604 bipolar patients: The role of predominant polarity. *J Affect Disord*. 2011; 133(3):443-449. doi:10.1016/j.jad.2011.04.055.

11 Baldassano CF, Marangell LB, Gyulai L, et al. Gender differences in bipolar disorder: Retrospective data from the first 500 STEP-BD participants. *Bipolar Disord*. 2005; 7(5):465-470. doi:10.1111/j.1399-5618.2005.00237.x.

12 Slyepchenko A, Frey BN, Lafer B, Nierenberg AA, Sachs GS, Dias RS. Increased illness burden in women with comorbid bipolar and premenstrual dysphoric disorder: data from 1 099 women from STEP-BD study. *Acta Psychiatr Scand*. 2017; 136(5):473-482. doi:10.1111/acps.12797.

13 Tondo L, Baldessarini RJ. Rapid cycling in women and men with bipolar manic-depressive disorders. *Am J Psychiatry*. 1998; 155(10):1434-1436. doi:10.1176/ajp.155.10.1434.

14 Diflorio A, Jones I. Is sex important Gender differences in bipolar disorder. *Int Rev Psychiatry*. 2010; 22(5):437-452. doi:10.3109/09540261.2010.514601

15 Arnold LM, McElroy SL, Keck PE. The role of gender in mixed mania. *Compr Psychiatry*. 2000; 41(2):83-87. doi:10.1016/S0010-440X(00)90137-8.

16 Clements C, Morriss R, Jones S, Peters S, Roberts C, Kapur N. Suicide in bipolar disorder in a national English sample, 1996-2009: Frequency, trends and characteristics. *Psychol Med*. 2013; 43(12):2593-2602. doi:10.1017/S0033291713000329.
17 Hendrick V, Altshuler LL, Gitlin MJ, Delrahim S, Hammen C. Gender and bipolar illness. J Clin Psychiatry. 2000; 61(5):393-396. doi:10.4088/JCP.v61n0514.

18 Suppes T, Mintz J, McElroy SL, et al. Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: A sex-specific phenomenon. Arch Gen Psychiatry. 2005; 62(10):1089-1096. doi:10.1001/archpsyc.62.10.1089.

19 Altshuler LL, Kupka RW, Hellemann G, et al. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Outcome Network. Am J Psychiatry. 2010; 167(6):708-715. doi:10.1176/appi.ajp.2009.09010105.

20 Clemente AS, Diniz BS, Nicolato R, et al. Bipolar disorder prevalence: A systematic review and meta-analysis of the literature. Rev Bras Psiquiatr. 2015; 37(2):155-161. doi:10.1590/1516-4446-2012-1693.

21 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edi. Arlington, VA: American Psychiatric Publishing, Inc.; 1994.

22 Culpepper L. Misdiagnosis of bipolar depression in primary care practices. J Clin Psychiatry. 2014; 75(3). doi:10.4088/JCP.13019tx1c.

23 Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RMA. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord. 1994; 31(4):281-294. doi:10.1016/0165-0327(94)90104-X.

24 Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: How far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 Survey of individuals with bipolar disorder. J Clin Psychiatry. 2003; 64(2):161-174. doi:10.4088/JCPv64n0209.

25 Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry. 1987; 144(11):1403-1411. doi:10.1176/ajp.144.11.1403.

26 Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: A Swedish national cohort study. JAMA Psychiatry. 2013; 70(9):931-939. doi:10.1001/jamapsychiatry.2013.1394.

27 Karanti A, Bobeck C, Osterman M, et al. Gender differences in the treatment of patients with bipolar disorder: A study of 7354 patients. J Affect Disord. 2015; 174:303-309. doi:10.1016/j.jad.2014.11.058.

28 Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014. Br J Psychiatry. 2017; 211(3):175-181. doi:10.1192/bjp.bp.117.202606.
29  Kim L, Kim J-A, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. *Epidemiol Health*. 2014; 36. doi:10.4178/EPIH/E2014008.

30  Yoon W, Shon SH, Hong Y, Joo YH, Lee JS. Antidepressant prescription patterns in bipolar disorder: A nationwide, register-based study in Korea. *J Korean Med Sci*. 2018; 33(46). doi:10.3346/jkms.2018.33.e290.

31  Bareis N, Lu J, Kirkwood CK, Kornstein SG, Wu E, Mezuk B. Identifying clinical net benefit of psychotropic medication use with latent variable techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *J Affect Disord*. 2018; 238:147-155. doi:10.1016/j.jad.2018.05.063.

32  Bobo W V., Na PJ, Geske JR, McElroy SL, Frye MA, Biernacka JM. The relative influence of individual risk factors for attempted suicide in patients with bipolar I versus bipolar II disorder. *J Affect Disord*. 2018; 225:489-494. doi:10.1016/j.jad.2017.08.076.

33  Buoli M, Cesana BM, Maina G, et al. Correlates of current rapid-cycling bipolar disorder: Results from the Italian multicentric RENDiBi study. *Eur Psychiatry*. 2019; 62:82-89 doi:10.1016/j.eurpsy.2019.09.001.

34  Vieta E, Langosch JM, Figueira ML, et al. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). *Int J Neuropsychopharmacol*. 2013; 16(8):1719-1732. doi:10.1017/S1461145713000278.

35  Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: A genome-wide association study. *Lancet*. 2016; 387(10023):1085-1093. doi:10.1016/S0140-6736(16)00143-4.

36  Kalman JL, Papiol S, Forstner AJ, et al. Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. *Bipolar Disord*. 2019; 21(1):68-75. doi:10.1111/bdi.12659.

37  Ferrari AJ, Stockings E, Khoo JP, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. *Bipolar Disord*. 2016;18(5):440-450. doi:10.1111/bdi.12423

38  Carvalho AF, Dimellis D, Gonda X, Vieta E, McIntyre RS, Fountoulakis KN. Rapid cycling in bipolar disorder: A systematic review. *J Clin Psychiatry*. 2014; 75(6). doi:10.4088/JCP.13r08905.

39  Morgan VA, Mitchell PB, Jablensky A V. The epidemiology of bipolar disorder: Sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders. *Bipolar Disord*. 2005; 7(4):326-337. doi:10.1111/j.1399-5618.2005.00229.x.
40 Valentí M, Pacchiarotti I, Undurraga J, et al. Risk factors for rapid cycling in bipolar disorder. *Bipolar Disord.* 2015; 17(5):549-559. doi:10.1111/bdi.12288.

41 Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: A systematic review of randomized, controlled trials. *Am J Psychiatry.* 2004;161(9):1537-1547. doi:10.1176/appi.ajp.161.9.1537

42 Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. *N Engl J Med.* 2007;356(17):1711-1722. doi:10.1056/NEJMoa064135

43 Price LH, Tyrka AR. Adjunctive antidepressant treatment for bipolar depression [1]. *N Engl J Med.* 2007;357(6):614-616. doi:10.1056/NEJMc071459

44 Bodén R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: Population based cohort study. *BMJ.* 2012; 345(7883). doi:10.1136/bmj.e7085.

45 Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJM, Kushner SA, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: A systematic review and meta-analysis. *Am J Psychiatry.* 2016; 173(2):117-127. doi:10.1176/appi.ajp.2015.15010124.

46 Viguera AC, Tondo L, Koukopoulos AE, Reginaldi D, Lepri B, Baldessarini RJ. Episodes of mood disorders in 2,252 pregnancies and postpartum periods. *Am J Psychiatry.* 2011; 168(11):1179-1185. doi:10.1176/appi.ajp.2011.11010148.

47 Studd J, Panay N. Are oestrogens useful for the treatment of depression in women? *Best Pract Res Clin Obstet Gynaecol.* 2009; 23(1):63-71. doi:10.1016/j.bpobgyn.2008.11.001.

48 Joffe RT. Hormone treatment of depression. *Dialogues Clin Neurosci.* 2011; 13(1):127-138.

49 Graziottin A, Serafini A. Depression and the menopause: Why antidepressants are not enough? *Menopause Int.* 2009; 15(2):76-81. doi:10.1258/mi.2009.009021.

50 Robakis TK, Holtzman J, Stemmlle PG, Reynolds-May MF, Kenna HA, Rasgon NL. Lamotrigine and GABAA receptor modulators interact with menstrual cycle phase and oral contraceptives to regulate mood in women with bipolar disorder. *J Affect Disord.* 2015; 175:108-115. doi:10.1016/j.jad.2014.12.040.

51 Michl LC, McLaughlin KA, Shepherd K, Nolen-Hoeksema S. Rumination as a mechanism linking stressful life events to symptoms of depression and anxiety: Longitudinal evidence in early adolescents and adults. *J Abnorm Psychol.* 2013;122(2):339-352. doi:10.1037/a0031994

52 McLaughlin KA, Nolen-Hoeksema S. Rumination as a transdiagnostic factor in depression and anxiety. *Behav Res Ther.* 2011;49(3):186-193. doi:10.1016/j.brat.2010.12.006
Tables
Table 1
Main large samples (>1000 patients) studies on Bipolar Disorder published in the last ten years

| Authors | Site | Sample | N° of BD patients recruited | Female patients (%) |
|---------|------|--------|-----------------------------|---------------------|
| N. Bareis, J. Lu et al., 2018 | U.S.A. | STEP-BD (1999–2005) | 3563 | 57,65% |
| W. Bobo, P. Na et al., 2018 | U.S.A. | Mayo Clinic Biobank (started in 2009) | 1465 | BD-I = 69,42% BD-II = 30,58% | 60,75% BD-I = 58,60% BD-II = 66,10% |
| M. Buoli, M. B. Cesana et al., 2019 | Italy | RENDiBi Study (April 2014-March 2015) | 1675 | BD-I = 62,21% BD-II = 37,79% | 57,40% |
| C. Crump, K. Sundquist et al., 2013 | Sweden | National Registry (2001–2002) | 6618 | 59,20% |
| J. Hayes, L. Marston et al., 2017 | U.K. | Primary care electronics health records (THIN) (2000–2014) | 17341 | 58,83% |
| L. Hou, U. Heilbronner et al., 2016 | Australia, Canada, Czech Republic, France, Germany, Italy, Japan, Poland, Romania, Spain, Sweden, Switzerland, Taiwan, U.S.A. | ConLiGen | 2563 | 57,63% |
| J. L. Kalman, S. Papiol et al., 2019 | Austria, Australia, Canada, Czech Republic, France, Germany, Italy, Poland, Romania, Spain, Sweden, U.S.A. | ConLiGen, Bonn-Mannheim and PsyCourse | 1995 (BD-I patients only) | 55,10% |
| A. Karanti, C. Bobeck et al., 2014 | Sweden | Swedish National Quality Assurance Register for Bipolar Disorder (BipoläR) (2004–2011) | 7136 | BD-I = 47,09% BD-II = 38,15% BD-NOS = 14,76% | 61,27% BD-I = 57,30% BD-II = 64,95% BD-NOS = 64,42% |
| Authors                          | Site                                                                 | Sample                                    | N° of BD patients recruited | Female patients (%) |
|---------------------------------|----------------------------------------------------------------------|-------------------------------------------|----------------------------|---------------------|
| E. Vieta, J. M. Langosch et al., 2013 | Austria, Belgium, Brazil, France, Germany, Portugal, Romania, Turkey, Ukraine, Venezuela | WAVE-BD (April 2010-June 2011)            | 2896                       | BD-I = 68,70%       |
|                                 |                                                                     |                                           |                            | BD-II = 31,3%       |
| W. Yoon, S-H. Shon et al., 2018 | Korea                                                               | Korean HIRA-NPS (2013 sample only)        | 2626                       | 58,80%              |

**THIN** = The Health Improvement Network; **STEP-BD** = Systematic Treatment Enhancement Program for Bipolar Disorder; **RENDiBi** = National Epidemiological Research on Bipolar Disorder; **HIRA-NPS** = Health Insurance Review and Assessment Service – National Patient Sample; **WAVE-BD** = Wide Ambispective of Bipolar Disorder; **ConLiGen** = The International Consortium on Lithium Genetics; **BD-I** = Bipolar Disorder type I

**Figures**

![Figure 1](image-url)
Gender distribution in Bipolar Disorder as shown in the main large sample studies of the last ten years a) Graphic representation of gender distribution in 9 main large sample studies, reported as percentage of female and male participants upon the total number of BD patients; b) percentages of females and males in BD type-specific samples; c) gender distribution of three samples, confronted with the BD type-specific composition of the samples. BDI = Bipolar Disorder type I; BDII = Bipolar Disorder type II. N°1) N. Bareis, J. Lu et al., 2018, U.S.A., STEP-BD (1999-2005), n° of BD patients = 3563, (%) of female patients = 57,65%; N°2) W. Bobo, P. Na et al., 2018, U.S.A., Mayo Clinic Biobank (started in 2009), n° of BD patients = 1465, BD-I = 69,42%, BD-II = 30,58%, (%) of female patients = 60,75%, BD-I = 58,60%, BD-II = 66,10%; N°3) M. Buoli, M. B. Cesana et al., 2019, Italy, RENDiBi Study (April 2014-March 2015), n° of BD patients = 1675, BD-I = 62,21%, BD-II = 37,79%, (%) of female patients = 57,40%; N°4) C. Crump, K. Sundquist et al., 2013, Sweden, National Registry (2001-2002), n° of BD patients = 6618, (%) of female patients = 59,20%; N°5) J. Hayes, L. Marston et al., 2017, U.K., Primary care electronics health records (THIN) (2000-2014), n° of BD patients = 17341, (%) of female patients = 58,83%; N°6) L. Hou, U. Heilbronner et al., 2016, Australia, Canada, Czech Republic, France, Germany, Italy, Japan, Poland, Romania, Spain, Sweden, Switzerland, Taiwan, U.S.A., ConLiGen, n° of BD patients = 2563, (%) of female patients = 57,63%; N°7) J. L. Kalman, S. Papiol et al., 2019, Austria, Australia, Canada, Czech Republic, France, Germany, Italy, Poland, Romania, Spain, Sweden, U.S.A., ConLiGen, Bonn-Mannheim and PsyCourse, n° of BD patients = 1995 (BD-I patients only), (%) of female patients = 55,10%; N°8) A. Karanti, C. Bobeck et al., 2014, Sweden, Swedish National Quality Assurance Register for Bipolar Disorder (BipoläR) (2004-2011), n° of BD patients = 7136, BD-I = 47,09%, BD-II = 38,15%, BD-NOS = 14,76%, (%) of female patients = 61,27%, BD-I = 57,30%, BD-II = 64,95%, BD-NOS = 64,42%, N°9) E. Vieta, J. M. Langosch et al., 2013, Austria, Belgium, Brazil, France, Germany, Portugal, Romania, Turkey, Ukraine, Venezuela, WAVE-BD (April 2010- June 2011), n° of BD patients = 2896, BD-I = 68,70%, BD-II = 31,3%, (%) of female patients = 65,00%; N°10) W. Yoon, S-H. Shon et al., 2018, Korea, Korean HIRA-NPS (2013 sample only), n° of BD patients = 2626, (%) of female patients = 58,80%. THIN = The Health Improvement Network; STEP-BD = Systematic Treatment Enhancement Program for Bipolar Disorder; RENDiBi = National Epidemiological Research on Bipolar Disorder; HIRA-NPS = Health Insurance Review and Assessment Service – National Patient Sample; WAVE-BD = Wide Ambispective of Bipolar Disorder; ConLiGen = The International Consortium on Lithium Genetics; BD-I = Bipolar Disorder type I.